|
|
|
|
| LEADER |
01563nam a2200241 u 4500 |
| 001 |
EB002000928 |
| 003 |
EBX01000000000000001163829 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a Clinical review report: Ticagrelor (Brilinta)
|h Elektronische Ressource
|b indication : co‐administered with low‐dose acetylsalicylic acid (ASA: 75‐150 mg), is indicated for the secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event
|
| 246 |
3 |
1 |
|a Ticagrelor (Brilinta)
|
| 246 |
3 |
1 |
|a CDR clinical review report for Brilinta
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2016, August 2016
|
| 300 |
|
|
|a 1 PDF file (viii, 52 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK539147
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The objective was to perform a systematic review of the beneficial and harmful effects of ticagrelor 60 mg and 90 mg tablets co-administered with low-dose (75 mg to 150 mg) acetylsalicylic acid, for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction that occurred at least one year ago, and a high risk of developing an atherothrombotic event
|